Home
About
Overview
Sharing Data
ORCID
Help
History (19)
Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
Long-term impact of treatment in women diagnosed with bulimia nervosa.
Sensing hypoxia: carotid body mechanisms and reflexes in health and disease.
Executive summary: Kidney Early Evaluation Program (KEEP) 2008 annual data report.
Chimerism does not predict for outcome after alemtuzumab based conditioning.
See All 19 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Chimerism does not predict for outcome after alemtuzumab based conditioning.
Chimerism does not predict for outcome after alemtuzumab based conditioning. Bone Marrow Transplant. 2007 Jul; 40(2):181.
View in:
PubMed
subject areas
Alemtuzumab
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Neoplasm
Graft vs Host Disease
Hematologic Neoplasms
Humans
Stem Cell Transplantation
Transplantation Chimera
Transplantation Conditioning
Transplantation, Homologous
Treatment Outcome
authors with profiles
Wendy Stock
Koen Van Besien